Gilead Sciences is investing $250m in LEO Pharma’s preclinical small molecules. According to the deal, Gilead will develop oral versions of the potential inflammation drugs, while Denmark’s LEO will focus on topical versions. Additional payments of up to $1.7bn could go to LEO, depending on the research’s progress. The molecules are being developed to target IL-4 and IL-13 proteins, known to be linked to inflammation.

North Korean Hackers Use Fake U.S. Companies to Spread Malware in Crypto Industry: Report
North Korean hackers reportedly set up shell companies in the US to penetrate the crypto sector and target developers via fake job offers, according to